ANP SP & Mkt cap should at least be equal to the risk weighted...

ANP SP & Mkt cap should at least be equal to the risk weighted NPV of the anticipated value of a Duchenne's deal with pharma done ASAP after the DMD P2b results are in Q3/Q4 '24. however, the current $.053 SP is a long, long way short of that. Why? Three reasons IMO. There was a lot of impatient money in the last cap raise and it is now exiting while there is still a bit of profit on the table. Second, the 7 mill of options issued to CG at a ridiculous zero performance incentive premium conveys pessimism, not optimism. And third, it remains unclear at this time whether the DMD patient recruiting is going to plan. If JG reports in the next 1- 2 months that recruiting is going to plan, the SP definitely deserves an uptick. The major value inflexion uplift should occur in '24 when either a DMD licensing deal is done with pharma or ANP is acquired. Acquisition would be by far the best outcome for shareholders even if it was a combo of cash & equity. Remaining independent long term in OZ is a prescription for joining dozens of OZ biotechs in the living dead. JG must not let this happen.